UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Biological treatments for systemic lupus erythematosus

Isenberg, D; Leckie, MJ; (2002) Biological treatments for systemic lupus erythematosus. Scandinavian Journal of Rheumatology , 31 (4) pp. 187-191.

Full text not available from this repository.

Abstract

There have been many recent advances in therapeutic approaches to systemic lupus erythematosus (SLE). The roles of cyclophosphamide, hydroxychloroquine, methotrexate and hormonal treatments in the management of SLE have been investigated in recent randomised controlled trials (1). However, although these pharmacological agents have a role to play in some patients with lupus, broad based effects have led to problems with side effects and adverse reactions. For this reason, more specific therapies are urgently required. Such strategies currently under evaluation include altering the cytokine balance, reducing T cell activation and inducing tolerance, blocking T cell costimulatory molecules, reducing auto-antibody production from B cells, targetting specific genes and stem cell transplantation. These are known as "biological" treatments as their aim is to alter patho- physiological processes occurring in the diseased state. This review will focus on the biological therapies currently under investigation- with particular attention on the cytokine-directed therapies

Type: Article
Title: Biological treatments for systemic lupus erythematosus
Additional information: UI - 22256402 LA - eng RN - 0 (Biological Products) PT - Editorial PT - Review PT - Review Literature DA - 20021008 IS - 0300-9742 SB - IM CY - Norway
Keywords: ACTIVATION, advances, ADVERSE, AGENT, AGENTS, As, Attention, Autoantibodies, B CELL, B CELLS, B-cell, B-CELLS, balance, Biological Products, biological therapy, cell, Cell Transplantation, CELLS, CONTROLLED TRIAL, CONTROLLED TRIALS, COSTIMULATORY MOLECULES, Cyclophosphamide, cytokine, editorial, effects, evaluation, FOCUS, GENE, Genes, hydroxychloroquine, IM, immunology, Immunotherapy, LA, literature, Lupus, Lupus Erythematosus, Systemic, Management, Methotrexate, Molecule, MOLECULES, Patient, patients, Pharmacological, PHYSIOLOGICAL, play, Problems, process, processes, product, production, PRODUCTS, Randomised controlled trial, Randomised Controlled Trials, Recent Advances, Review, Review Literature, ROLES, side effect, side effects, SLE, STATE, STEM, stem cell, stem cell transplantation, STEM-CELL, strategies, strategy, SYSTEMIC, SYSTEMIC LUPUS ERYTHEMATOSUS, SYSTEMIC-LUPUS-ERYTHEMATOSUS, T cell, T cell activation, T-CELL, therapeutic, therapeutic use, THERAPIES, therapy, tolerance, transplantation, treatment, Treatments, TRIAL, TRIALS
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation
URI: http://discovery.ucl.ac.uk/id/eprint/28621
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item